Alphabet (GOOGL) shares fell 2.42% after news broke that its Google-backed drug-discovery unit, Isomorphic Labs, pushed its first clinical trials back until late 2026.
- This delay tempers the speculative long-term outlook and trims a key potential upside driver for the 'Other Bets' portfolio.
- The price decline occurred amid profit-taking following strong 2025 gains.
- Option traders were noted as moderately bearish, even as the core Gemini AI models maintain strong commercial traction.